Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.01
>-AU$0.01(-8.33%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-8.33%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume169.96K
Average Volume (3M)653.10K
Market Cap
AU$5.50M
Enterprise ValueAU$5.85
Total Cash (Recent Filing)AU$1.71M
Total Debt (Recent Filing)AU$2.52M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.09%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding611,654,100
10 Day Avg. Volume635,960
30 Day Avg. Volume653,097
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Bulls Say, Bears Say
Bulls Say
2026 Revenue ReboundThe strong 2026 revenue rebound indicates that Acrux regained commercial activity after two difficult years. If the improvement persists, a larger revenue base could support operating leverage, improve resource utilisation, and provide a stronger foundation for rebuilding the business over the next several quarters.
Positive 2026 Cash FlowPositive operating and free cash flow in 2026 is an important improvement because it shows the business generated cash despite remaining accounting losses. Sustained cash generation would reduce reliance on external funding and provide greater flexibility to support operations and future commercial activity.
Narrowing Net LossA materially smaller net loss shows that financial performance improved meaningfully from the prior year, even though profitability has not yet been achieved. Continued narrowing could bring Acrux closer to breakeven, reduce cash requirements, and make future revenue growth more valuable to shareholders.
Bears Say
Persistent UnprofitabilityPersistent net, EBIT, and EBITDA losses indicate that Acrux has not yet demonstrated a sustainable profit model. Continued operating losses can consume financial resources, limit internal funding capacity, and make the company more exposed if revenue growth slows or expenses rise.
Highly Volatile RevenueThe large swings in annual revenue make the recent rebound harder to treat as a stable trend. Such volatility complicates planning, weakens confidence in recurring commercial momentum, and increases the risk that earnings and cash generation could deteriorate again if revenue normalises.
Weaker Balance SheetHigher leverage combined with a substantially compressed equity base leaves Acrux with a weaker financial cushion. This reduces flexibility for absorbing recurring losses, increases the importance of maintaining positive cash generation, and may constrain the company’s ability to fund growth internally.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$5.50M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 153 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -AU$0.002 earnings per share for the quarter.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of 9.09%. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 611,654,100 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:ACR Sentiment 50%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$149.6K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―